Modeling the Cost-Effectiveness of a Polypill to Prevent Cardiovascular Disease

Use of a polypill in a majority Black and low-income patient cohort was predicted to be lifesaving and cost-effective.

The Southern Community Cohort Study (SCCS) Polypill Trial showed that a cardiovascular polypill (a single, fixed-dose pill containing atorvastatin 10 mg, amlodipine 2.5 mg, losartan 25 mg, and hydrochlorothiazide 12.5 mg) could control blood pressure and low-density lipoprotein cholesterol in a majority Black and low-income population without cardiovascular disease (CVD). To investigate the cost-effectiveness of the polypill, researchers performed simulations using data from published literature, the U.S. National Health and Nutrition Examination Survey (NHANES), pooled cohort studies, and the SCCS Polypill Trial itself.

For the modeling, polypill treatment was priced at $463 per year. Using a sample of 100,000 NHANES participants who were r…

Reviewing Author

Karol E. Watson, MD, PhD, FACC

Disclosures

Consultant/Advisory BoardBoehringer Ingelheim; Amgen; Novartis; Lilly; Amarin

Speaker’s BureauBoehringer Ingelheim

Grant/Research SupportNIH

Editorial BoardsCirculation (Associate Editor)